These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1175 related articles for article (PubMed ID: 25239345)

  • 41. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy.
    Barugola G; Partelli S; Crippa S; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
    Am J Surg; 2012 Feb; 203(2):132-9. PubMed ID: 21824596
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of preoperative radiochemotherapy in patients with locally advanced pancreatic carcinoma.
    Lind PA; Isaksson B; Almström M; Johnsson A; Albiin N; Byström P; Permert J
    Acta Oncol; 2008; 47(3):413-20. PubMed ID: 17882555
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chemoradiation for resected pancreatic adenocarcinoma with or without intraoperative radiation therapy boost: Long-term outcomes.
    Calvo FA; Sole CV; Atahualpa F; Lozano MA; Gomez-Espi M; Calin A; García-Alfonso P; Gonzalez-Bayon L; Herranz R; García-Sabrido JL
    Pancreatology; 2013; 13(6):576-82. PubMed ID: 24280572
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pancreatic carcinoma deemed unresectable at exploration may be resected for cure: an institutional experience.
    Chao C; Hoffman JP; Ross EA; Torosian MH; Eisenberg BL
    Am Surg; 2000 Apr; 66(4):378-85; discussion 386. PubMed ID: 10776876
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Does intraoperative radiation therapy improve local tumor control in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma? A propensity score analysis.
    Showalter TN; Rao AS; Rani Anne P; Rosato FE; Rosato EL; Andrel J; Hyslop T; Xu X; Berger AC
    Ann Surg Oncol; 2009 Aug; 16(8):2116-22. PubMed ID: 19437078
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer.
    Wo JY; Niemierko A; Ryan DP; Blaszkowsky LS; Clark JW; Kwak EL; Lillemoe KD; Drapek LN; Zhu AX; Allen JN; Faris JE; Murphy JE; Nipp R; Fernandez-Del Castillo C; Ferrone CR; Hong TS
    Am J Clin Oncol; 2018 Jul; 41(7):656-661. PubMed ID: 28134673
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preoperative chemoradiation reduces the risk of pancreatic fistula after distal pancreatectomy for pancreatic adenocarcinoma.
    Takahashi H; Ogawa H; Ohigashi H; Gotoh K; Yamada T; Ohue M; Miyashiro I; Noura S; Kishi K; Motoori M; Shingai T; Nakamura S; Nishiyama K; Yano M; Ishikawa O
    Surgery; 2011 Sep; 150(3):547-56. PubMed ID: 21621236
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The natural history of resected pancreatic cancer without adjuvant chemotherapy.
    Hernandez JM; Morton CA; Al-Saadi S; Villadolid D; Cooper J; Bowers C; Rosemurgy AS
    Am Surg; 2010 May; 76(5):480-5. PubMed ID: 20506876
    [TBL] [Abstract][Full Text] [Related]  

  • 49. En bloc vascular resection for locally advanced pancreatic malignancies infiltrating major blood vessels: perioperative outcome and long-term survival in 136 patients.
    Yekebas EF; Bogoevski D; Cataldegirmen G; Kunze C; Marx A; Vashist YK; Schurr PG; Liebl L; Thieltges S; Gawad KA; Schneider C; Izbicki JR
    Ann Surg; 2008 Feb; 247(2):300-9. PubMed ID: 18216537
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Study.
    Ruarus AH; Vroomen LGPH; Geboers B; van Veldhuisen E; Puijk RS; Nieuwenhuizen S; Besselink MG; Zonderhuis BM; Kazemier G; de Gruijl TD; van Lienden KP; de Vries JJJ; Scheffer HJ; Meijerink MR
    Radiology; 2020 Jan; 294(1):212-220. PubMed ID: 31687922
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
    Hashemi-Sadraei N; Gbolahan OB; Salfity H; O'Neil B; House MG; Shahda S
    Am J Clin Oncol; 2018 Oct; 41(10):982-985. PubMed ID: 28968257
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment of locally advanced pancreatic cancer by percutaneous and intraoperative irreversible electroporation: general hospital cancer center experience.
    Lambert L; Horejs J; Krska Z; Hoskovec D; Petruzelka L; Krechler T; Kriz P; Briza J
    Neoplasma; 2016; 63(2):269-73. PubMed ID: 26774149
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Preoperative CA 19-9 level is an important prognostic factor in patients with pancreatic adenocarcinoma treated with surgical resection and adjuvant concurrent chemoradiotherapy.
    Hallemeier CL; Botros M; Corsini MM; Haddock MG; Gunderson LL; Miller RC
    Am J Clin Oncol; 2011 Dec; 34(6):567-72. PubMed ID: 21150564
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma.
    Narayanan G; Hosein PJ; Arora G; Barbery KJ; Froud T; Livingstone AS; Franceschi D; Rocha Lima CM; Yrizarry J
    J Vasc Interv Radiol; 2012 Dec; 23(12):1613-21. PubMed ID: 23177107
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Locally advanced pancreatic duct adenocarcinoma: pancreatectomy with planned arterial resection based on axial arterial encasement.
    Perinel J; Nappo G; El Bechwaty M; Walter T; Hervieu V; Valette PJ; Feugier P; Adham M
    Langenbecks Arch Surg; 2016 Dec; 401(8):1131-1142. PubMed ID: 27476146
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Percutaneous CT-guided irreversible electroporation followed by chemotherapy as a novel neoadjuvant protocol in locally advanced pancreatic cancer: Our preliminary experience.
    Belfiore MP; Ronza FM; Romano F; Ianniello GP; De Lucia G; Gallo C; Marsicano C; Di Gennaro TL; Belfiore G
    Int J Surg; 2015 Sep; 21 Suppl 1():S34-9. PubMed ID: 26118600
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer.
    Rashid OM; Pimiento JM; Gamenthaler AW; Nguyen P; Ha TT; Hutchinson T; Springett G; Hoffe S; Shridhar R; Hodul PJ; Johnson BL; Illig K; Armstrong PA; Centeno BA; Fulp WJ; Chen DT; Malafa MP
    Ann Surg Oncol; 2016 Apr; 23(4):1371-9. PubMed ID: 26661409
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluating the Regulatory Immunomodulation Effect of Irreversible Electroporation (IRE) in Pancreatic Adenocarcinoma.
    Pandit H; Hong YK; Li Y; Rostas J; Pulliam Z; Li SP; Martin RCG
    Ann Surg Oncol; 2019 Mar; 26(3):800-806. PubMed ID: 30610562
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Locally advanced pancreatic adenocarcinoma. Chemoradiotherapy, reevaluation and secondary resection].
    Delpero JR; Turrini O
    Cancer Radiother; 2006 Nov; 10(6-7):462-70. PubMed ID: 16987678
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Locally advanced pancreatic adenocarcinoma: reassessment of response with CT after neoadjuvant chemotherapy and radiation therapy.
    Cassinotto C; Mouries A; Lafourcade JP; Terrebonne E; Belleannée G; Blanc JF; Lapuyade B; Vendrely V; Laurent C; Chiche L; Wagner T; Sa-Cunha A; Gaye D; Trillaud H; Laurent F; Montaudon M
    Radiology; 2014 Oct; 273(1):108-16. PubMed ID: 24960211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 59.